Submit Justification and Rational: CDSCO Panel tells Pfizer on protocol amendment proposal for Palbociclib
New Delhi: In response to the proposal presented by the drug major Pfizer for the protocol amendment, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended the firm to submit the justification and rationale for the proposed amendment of the anti-cancer drug Palbociclib. This came after the firm […]